Rheumatoid Arthritis

Phase 3 of the FUTURE 5 trial further examined the efficacious effect that secukinumab had on patients with psoriatic arthritis.

The fifth update from the American College of Rheumatology supports fourth doses of the vaccine for high-risk rheumatic disease patients.

Less than 5% of patients with IBD treated with azathioprine had white blood count, eGFR, ALT, and neutrophil abnormalities.

The FDA was prompted to require a safety trial comparing tofacitinib with TNF inhibitors in patients with rheumatoid arthritis.

Promising results were announced by UCB after a Phase 3 study evaluated bimekizumab for non-radiographic axial spondyloarthritis and met all endpoints.

This study shows that many patients with rheumatoid arthritis can use a dose lower than 1000mg and still see results.

New ACR findings suggest patients taking the common biologic drug closely leading up to their vaccination may not have a humoral response to it.

Data show participants with early glucocorticoid use were more likely to be prescribed a biologic by 12 months, in comparison to non-users.

The study examines the impact of antirheumatic treatment on pregnancy outcomes in women with psoriatic arthritis.

During this video interview, Dr. Jay Mehta talks about his approach to explaining such complex medical conditions and treatments to his pediatric patients and their families.

Dr. Mehta talks about rheumatologic testing, joint examinations, and the great relationships he gets to develop with his patients.

Dr. Mehta highlights some of the challenges that come with treating pediatric rheumatology patients and how he handles them.

In this video interview, Dr. Jay Mehta discusses his presentation on pediatric rheumatology for the American Association of Pediatrics Conference.

The 2 studies focused on upadacitinib treatment for one group of patients with ankylosing spondylitis and another group of patients with non-radiographic axial spondyloarthritis.

Looking specifically at patients who have been treated with biologic disease-modifying anti-rheumatic drugs, this study examines the risk of new or recurrent cancer.

Investigators analyze the differences between SARS-CoV-2 testing and risk of infection.

Investigators found no significant differences in the efficacy and safety of the originator or biosimilars in children with juvenile idiopathic arthritis.

Investigators gathered data from vulnerable populations with rheumatic disease regarding their thoughts and opinions on the COVID-19 virus.

Dr. Blauvelt speaks on the results of the phase 3b Heads Up study, and the future of upadacitinib and dupilumab in atopic dermatitis management.

Investigators from Turkey show how static foot posture in patients with rheumatic diseases can lead to impairment of physical function due enthesitis.

Researchers from Texas determined the global prevalence of OSA using 8 unique studies involving patients with rheumatoid arthritis from around the world.

New findings show patients with osteoarthritis and rheumatoid arthritis share comorbidities that contribute to an increased likelihood of frailty, especially in older populations.

A higher proportion of patients with immune-mediated diseases experienced ≥1 thromboembolic events at baseline compared to those without an IMD.

Research reveals microtrauma and swelling in the joints surrounding the thumb, conditions that are predominantly features in patients with psoriatic arthritis than any other arthritic diseases.

The investigators linked immediate biological responses and symptomatic and structural outcomes to long-term injuries in active patients.

New research shows clinical effectiveness in increasing biologic doses in children, depending on the agent.

Investigators push for messaging transparency and consistency from health care professionals in regard to arthritis medication.

Of the 44 new recommendations, 7 were strongly recommended.

Data show 89 of 602 patients with rheumatoid arthritis had renal damage, with patients predominantly female and older age.